Eculizumab (Soliris) for paroxysmal nocturnal hemoglobinuria.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004334:Drug Administration Schedule; D016527:Drug Costs; D006401:Hematologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006401:Hematologic Agents; C481642:eculizumab